There is no association of serum vitamin B levels with all‐cause and cardiovascular mortality in hemodialysis patients. Issue 3 (21st December 2022)

• Record Type: Journal Article
• Authors: Wang, Yan; Yang, Bing; Zhu, Li; Ni, Meng‐fan; Gan, Liang‐ying; Wang, Mei; Zuo, Li
• Is Part Of: Therapeutic apheresis and dialysis. Volume 27:Issue 3(2023)
• Page Start: 571
• Page End: 579
• Publication Date: 2022-12-21
• Subjects: hemodialysis -- mortality -- vitamin B; Hemapheresis -- Periodicals; Dialysis -- Periodicals; Blood Component Removal -- Periodicals; Renal Dialysis -- Periodicals; Hémaphérèse -- Périodiques; Dialyse -- Périodiques; Sang -- Collecte et conservation -- Périodiques; 616
• DOI: 10.1111/1744-9987.13959
• Languages: English
• ISSNs: 1744-9979

Abstract

Abstract: Introduction: The impact of vitamin B metabolic disorders on hemodialysis (HD) patients' survival is unknown. This study is to investigate the association of serum vitamin B1, B3, B5, and B6 with all‐cause and cardiovascular (CV) mortality in HD patients. Methods: Patients' baseline serum vitamin B1, B3, B5, and B6 levels were collected, and they were followed up for the occurrence of all‐cause and CV death. Kaplan–Meier analysis and Cox proportional hazards model were used to examine the association of vitamin B with mortality. Results: Seventy‐six HD patients were included. The median follow‐up time was 99 months. Kaplan–Meier analysis showed that baseline vitamin B5 < 69.0 nmol/L and vitamin B6 < 8.1 ng/ml were associated with a higher risk of CV mortality, but these associations were nullified after adjustment. Conclusions: Serum vitamins B1, B3, B5, and B6 were not associated with all‐cause or CV mortality in HD patients. Clinical Trial Registry : ChiCTR2200057078 (Chinese Clinical Trial Registry, https://www.chictr.org.cn/ ).